Skip to content
Menu

Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $66 to $48.

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $66 to $48.

Read at benzinga.com

← All stock news